Clearmind Medicine Inc. (CMND)

Clearmind Medicine Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Net Income	-6.64	-3.86	-5.25	-8.62	-6.89	-2.73
Depreciation & Amortization	0.05	0.05	0.05	0.06	0.08	0
Stock-Based Compensation	1.84	0.81	1	0.83	1.21	0.62
Other Adjustments	-1.24	-1.69	-0.52	2.4	0.64	0.01
Change in Receivables	-0.04	0.02	0.06	-0.15	0.02	-0.12
Changes in Other Operating Activities	0.28	-0.06	-0.2	-0.81	1.22	0.13
Operating Cash Flow	-5.55	-4.73	-4.86	-6.3	-3.72	-2.08
Capital Expenditures	-	-	-	-	-0.01	-0.02
Purchases of Intangible Assets	-	-	-	-	-	-0.15
Purchases of Investments	-0.87	-0.71	-0.35	-	-	-
Proceeds from Sale of Investments	0.14	0.19	0.08	-	-	-
Other Investing Activities	-0.01	-0.01	0.03	-0.03	-	-0.02
Investing Cash Flow	-0.61	-0.54	-0.24	-0.03	-0.01	-0.18
Long-Term Debt Issued	-	2.25	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-	2.25	-	-	-	-
Issuance of Common Stock	7.64	0.42	6.3	11.71	0.58	5.39
Net Common Stock Issued (Repurchased)	7.64	0.42	6.3	11.71	0.58	5.39
Other Financing Activities	-0.04	-0.04	-0.04	-0.04	-0.07	-
Financing Cash Flow	9.63	2.62	6.25	11.66	0.51	5.39
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	0	-0.01	-0.04	-0.02	-
Net Cash Flow	3.48	-2.65	1.15	5.3	-3.24	3.13
Free Cash Flow	-5.55	-4.73	-4.86	-6.3	-3.73	-2.09
Free Cash Flow Per Share	-14.26	-37.25	-62.69	-1244.86	-3443.00	-2709.79
Levered Free Cash Flow	-3.53	-1.61	-5.4	-9.38	-5.6	-2.61
Unlevered Free Cash Flow	-7.46	-5.57	-5.44	-7.05	-4.93	-2.58

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q